Fred Dotzler (Chairman), is a Managing Director and founder of De Novo Ventures, prior founder and General Partner at Medicus Venture Partners and prior General Partner of Crosspoint Venture Partners. Previous life science investments include Advanced Surgical Intervention, Anergen, Anesta, Applied Molecular Evolution, Biosite, Informed Medical Communications, Microvention, Nektar, Omnicell, OncoMed, Renovis, and Tularik. He is currently a stakeholder and Board member of Astute Medical, Bayhill Therapeutics, and iScience International and is invested in OncoMed. He previously held management positions in sales, marketing, acquisitions, and manufacturing with Millipore Corporation, Merrimack Laboratories, G.D. Searle & Co., and IBM. He received his BS degree in Industrial Engineering from Iowa State University, MBA from the University of Chicago, and an advanced degree in Economics from the University of Louvain, Belgium. He is a member of the Advisory Board of the Journal of Private Equity and a Trustee of the Salk Institute.
Paul Goddard, PhD, was appointed Chairman of the Board of ARYx in 2003. He also held the position of Chief Executive Officer from 2005 until November 2011. In the period between 2000 and 2005, he served as chairman and part time executive of several companies including AP Pharma and XenoPort. From 1998 until 2000, he was Chief Executive Officer of Elan Pharmaceuticals, the largest division of Elan Corporation. He was Chief Executive Officer of Neurex Corporation from 1991 until 1998 when the company was acquired by Elan. Prior to 1991, Dr. Goddard held various senior management positions at SmithKline Beecham including senior vice president strategic marketing and senior vice president Far East region. He obtained his doctorate degree from St. Mary’s Hospital, London, in the area of etiology and pathophysiology of colon cancer. Dr. Goddard remains on the Board of Directors of AP Pharma, Adolor, and Onyx Pharmaceuticals.
Naheed Ismaili Misfeldt, MPH, is a Partner at Aberdare Ventures. She has played an instrumental role in numerous Aberdare investments including Pharmion, Mpex Pharmaceuticals and Clovis Oncology. Prior to Aberdare, she worked as an Associate at Bay City Capital and Chase H&Q. She received her BA in Molecular & Cell Biology from the University of California, Berkeley and an MPH from the Columbia School of Public Health. She is also a graduate of the Kauffman Fellows Program.
John P. Longenecker, Ph.D., President, CEO and Director, has over 25 years of executive management experience in the biopharmaceuticals industry and has participated in all aspects of company development including venture funding, public equity offerings, corporate partnering and management of collaborations, mergers and acquisitions. Prior to HemaQuest, Dr. Longenecker served as President, CEO and Director at Vitreoretinal Technologies (2009-2010). From 2002 until 2009 he was President, CEO and Director of Favrille Inc. a company developing therapeutic cancer vaccines for patients with lymphoma. He led Favrille through multiple private financings, an IPO in Jan 2005, and several additional equity financings, raising over $210 million dollars to support the company’s growth. Dr. Longenecker led the downsizing and eventual reverse acquisition of MyMedicalRecords.com, (now MMRGlobal) in early 2009, following the clinical trial failure of Favrille’s lead drug candidate. In 1992, Dr. Longenecker joined DepoTech as Senior Vice President of Research, Development and Operations. He was instrumental in taking DepoTech public in Sept 1995 and served as President from February 1998 to April 1999, during which time the company’s lead product, DepoCyt, was approved by the FDA. Following SkyePharma PLC’s acquisition of DepoTech in 1999, Dr. Longenecker served as President of SkyePharma Inc.(now Pacira, Inc.) and as a member of the Executive Committee for SkyePharma plc until joining Favrille in early 2002. From 1982 to 1992, Dr. Longenecker was at Scios, a biotechnology company in the San Francisco Bay Area. He was Vice-President and Director of Development at Scios from 1986 to 1992. Dr. Longenecker was also a Director of a number of Scios subsidiaries during this period including Meta Bio (a JV with Pfizer in diabetes and obesity) and Karo Bio (now a public company in Sweden). Dr. Longenecker holds a B.S. in Chemistry from Purdue University and a Ph.D. in Biochemistry from The Australian National University in Canberra, Australia. He was a post doctoral fellow at Stanford University prior to joining Scios. Dr. Longenecker currently serves as a member of Dean’s Leadership Council of the School of Science at Purdue and was recently recognized by the College of Science of Purdue University with the Distinguished Science Alumnus award. In addition, he serves on the Board of Directors of Pacira, Inc.
Ivor Royston, MD, is a Founding Managing Partner of Forward Ventures and prior founder of Hybritech, Inc. (later acquired by Lilly) and Idec Pharmaceuticals (later merged with Biogen). He is currently Chairman of the Board of LigoCyte and serves as a director on the Board of Syndax. He has been instrumental in the formation and development of Applied Molecular Evolution (acquired by Eli Lilly); Combichem (acquired by DuPont); Corixa (acquired by GlaxoSmithKline); Genesys Therapeutics (merged with Somatix and acquired by Cell Genesys); Morphotek (acquired by Eisai), TargeGen (acquired by Sanofi-Aventis) and Triangle Pharmaceuticals (acquired by Gilead). Dr. Royston was previously the Founding President and CEO of the Sidney Kimmel Cancer Center and an Oncology faculty member of the University of California, San Diego School of Medicine. He received his BA and MD from Johns Hopkins and completed post-doctoral training in internal medicine and oncology at Stanford University. He was appointed by President Clinton to a six-year term on the National Cancer Advisory Board and is an inductee in the San Diego Entrepreneur Hall of Fame.
Wayne Roe, MA, is a Managing Director of InCube Ventures, prior Founding Officer and Chairman of Covance Health Economics and Outcomes Services, and prior VP for Economic and Health Policy for the Health Industry Manufacturers Association. He currently serves on the Boards of Directors of Spinal Modulation Inc., Intrapace Inc., and Velocity Pharmaceutical Development Inc. He is an advisor to the Maryland Life Sciences Incubator, and is on the executive committee of the Maryland Angels Investment Fund. He played a major role in developing and executing successful commercialization and reimbursement strategies for several innovative biomedical products including several therapeutics in hematology. Mr. Roe received a MA in Political Economy from the State University of New York and a MA in Economics from the University of Maryland, and was a graduate in economics from Union College.
Armen Shanafelt, PhD, is a Venture Partner at Lilly Ventures, and has over 22 years of experience in the pharmaceutical, biotechnology and diagnostic businesses. Previously, he was CSO responsible for the generation of the early biotherapeutic pipeline for Eli Lilly and Company, spanning the therapeutic areas of oncology, endocrine, and neuroscience; prior to this he held leadership positions at Roche Diagnostics and Bayer. He currently serves as a director on the boards of Protagonist Therapeutics, and Sutro Biopharma and is a Kauffman Fellow (Class 14). He received a BS in chemistry and physics from Pacific Lutheran University, and his PhD in chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute, where he studied the structure-function relationships of cytokines and their receptors. He is an inventor on patents for biotherapeutics and diagnostic technologies, and has authored a range of publications including the strategic application of protein optimization to therapeutic protein development.
George Stamatoyannopoulos, MD, DSc, Co-founder, is Professor of Medicine, Pathology and Genome Sciences and Director of the Markey Molecular Medicine Center at the University of Washington in Seattle. He has been the recipient of the William Dameshek Prize and Stratton Medal of the American Society of Hematology, the Metcalf Prize of the International Society of Experimental Hematology, the Levine Prize of the American Society of Clinical Pathology, and has served as President of the American Society of Hematology and the founding President of the American Society of Gene Therapy. He has founded two other biotechnology companies, Targeted Genetics and Regulome. He received his MD, Doctor of Science degree and post-graduate training from the University of Athens and the Royal Hellenic Research Foundation.
James Woody, MD, PhD, is a General Partner at Latterell Venture Partners, and brings more than 25 years of pharmaceutical research and management experience to LVP. In addition to his duties at LVP, Jim is currently chairman of OncoMed Pharmaceuticals, where he previously served as the founding CEO and helped organize the formation of the company. Jim was formerly President of Roche Bioscience in Palo Alto, CA. Prior to that he served as Chief Scientific Officer and Senior Vice President of R & D for Centocor, where he was responsible for the discovery and early clinical development of Remicade, the first of the TNF inhibitor biologics. Prior to Centocor, Jim served as Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service. During his service career he organized and ran the Navy’s Bone Marrow Cell Purification and Transplantation Unit, and with colleagues in the Navy started the “National Marrow Donor Program” that exists today, and has helped many patients. Jim holds an M.D. from Loma Linda University, was trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. Jim has authored or co-authored over 140 publications.